A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

Inclusion criteria: * Patients must have histologically or cytologically confirmed progressive advanced or metastatic solid tumor of one of the following: * Platinum sensitive relapsed small cell lung cancer (module 1) * gBRCAm HER2-negative metastatic breast cancer (module 2) * gBRCAm ovarian cancer (modules 3 and 5) * Metastatic or relapsed Gastric cancer (adenocarcinoma) (module 4) * gBRCAm negative ovarian cancer (modules 6 and 7) * At least one measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (or magnetic resonance imaging \[MRI\] suitable for assessment as per RECIST 1.1. The baseline scan must be obtained within 28 days prior to the first dose of olaparib. * Male or female patients, age ≥18 years (≥19 years for South Korea) * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Life expectancy ≥12 weeks * Adequate organ and marrow function * Ability to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation. Patients should not have gastrointestinal illnesses that would preclude the absorption of olaparib, which is an oral agent. For the gastric cancer cohort, patients with a full or partial gastrectomy will be permitted. * Ability of patient to understand and the willingness to sign a written informed consent document prior to any protocol related procedures, including screening evaluations. * Female patients must either…